A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Phase 1
Completed
- Conditions
- Breast CancerNeoplasm MetastasisColorectal Neoplasms
- Interventions
- Registration Number
- NCT02124148
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.
- Detailed Description
The primary purpose of Parts A, B, C, D and E of this study is to determine a recommended dose level and schedule of prexasertib (an inhibitor of checkpoint kinase 1 and 2 \[CHK1/CHK2\] in combination with:
* cisplatin (Part A)
* cetuximab (Part B)
* pemetrexed (Part C)
* fluorouracil (Part D)
* LY3023414 (Part E) \[An inhibitor of phosphoinositide 3-kinase alpha (PI3K alpha) and mammalian target of rapamycin (mTOR), DNA-dependent protein kinase (DNA-PK), and other class I phosphoinositide 3-kinase (PI3K) family members\]
in participants with advanced or metastatic cancer.
Part A dose expansion of the study will evaluate the safety and toxicity of prexasertib at the recommended dose level in combination with cisplatin in participants with advanced or metastatic cancer, Part B dose expansion of the study will evaluate the safety and toxicity of prexasertib at the recommended dose level in combination with cetuximab in participants with advanced or metastatic colorectal cancer, Part C and D dose expansions have been removed and Part E dose expansion of the study will evaluate the safety and toxicity of prexasertib at the recommended dose level in combination with LY3023414 in participants with advanced or metastatic cancer, participants with PIK3CA mutations, or with advanced or metastatic breast cancer.
In Parts A and B the effect of adding granulocyte colony stimulating factor (G-CSF) to cisplatin in combination with prexasertib and cetuximab in combination with prexasertib will be explored. In Part A the effect of changing the schedule of prexasertib and cisplatin also will be explored. In Part B the effect of changing the schedule of prexasertib and cetuximab also will be explored.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 167
Inclusion Criteria
- Must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed
- Have adequate organ function
- Prior Therapies: Systemic treatments: must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have discontinued any cytotoxic therapies at least 28 days prior to study enrollment. Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment
- All parts except Part B, Part E2, and Part E3 dose expansion: Must have diagnosis of cancer that is advanced or metastatic
- Part B dose expansion: Must have confirmed Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type colorectal cancer that is metastatic or recurrent and has failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant of irinotecan or oxaliplatin
- Part E2 dose expansion: must have cancer that is advanced or metastatic and have prior documentation of a mutation of PIK3CA
- Part E3 dose expansion: must have advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer
- Must be available during the duration of the study and willing to follow the study procedures
- Parts A and B: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for six months following the last dose of study drug
- Parts C, D and E: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug
- If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feeding
- Part E: Are able to swallow capsules or tablets
Exclusion Criteria
- Have received more than 2 previous lines of cytotoxic chemotherapy (if receiving cisplatin, 5-FU or pemetrexed)
- Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment
- Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
- Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months
- Must not have a family history of long QTc syndrome
- Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome
- Must not have acute leukemia
- Part E: Have insulin-dependent (type I) diabetes or a history of gestational diabetes
- Part E: Prior treatment with a PI3K/mTOR inhibitor
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Prexasertib + LY3023414 (Part E) LY3023414 Part E: Prexasertib administered IV on day one and LY3023414 administered orally twice daily every 14 days. Part E will be expanded at the recommended dose in participants with advanced or metastatic cancer, participants with PIK3CA mutations (E2 expansion), or with advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer (E3 expansion). Participants may remain on treatment until discontinuation criteria are met. Prexasertib + Cisplatin (Part A) Cisplatin Part A: Prexasertib and cisplatin administered intravenously (IV) once every 21 days. Part A2: Prexasertib and cisplatin administered IV every 21 days; G-CSF administered subcutaneously (SC) starting approximately 24 hours after each prexasertib dose every 21 days. Part A3: Cisplatin administered IV on day one and prexasertib administered IV on day two once every 21 days. Part A Expansion: Part A, A2, and/or A3 may be expanded at the recommended dose. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + Cisplatin (Part A) G-CSF Part A: Prexasertib and cisplatin administered intravenously (IV) once every 21 days. Part A2: Prexasertib and cisplatin administered IV every 21 days; G-CSF administered subcutaneously (SC) starting approximately 24 hours after each prexasertib dose every 21 days. Part A3: Cisplatin administered IV on day one and prexasertib administered IV on day two once every 21 days. Part A Expansion: Part A, A2, and/or A3 may be expanded at the recommended dose. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + Pemetrexed (Part C) Pemetrexed Part C: Pemetrexed administered IV on day one and prexasertib administered IV on day one and two every 21 days. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + Cetuximab (Part B) Cetuximab Part B: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days. Part B2: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days; G-CSF administered SC starting approximately 24 hours after each prexasertib dose every 14 days. Part B3: Cetuximab administered IV with prexasertib administered IV once every 14 days. Part B Expansion: Part B, B2 and/or B3 may be expanded at the recommended dose. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + Cetuximab (Part B) G-CSF Part B: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days. Part B2: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days; G-CSF administered SC starting approximately 24 hours after each prexasertib dose every 14 days. Part B3: Cetuximab administered IV with prexasertib administered IV once every 14 days. Part B Expansion: Part B, B2 and/or B3 may be expanded at the recommended dose. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + 5-FU (Part D) Fluorouracil Part D: Leucovorin administered IV on day one, 5-FU administered IV bolus on day one and by continuous IV on days one to three (46 hours), and prexasertib administered IV on day three every 14 days. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + 5-FU (Part D) Leucovorin Part D: Leucovorin administered IV on day one, 5-FU administered IV bolus on day one and by continuous IV on days one to three (46 hours), and prexasertib administered IV on day three every 14 days. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + Cisplatin (Part A) Prexasertib Part A: Prexasertib and cisplatin administered intravenously (IV) once every 21 days. Part A2: Prexasertib and cisplatin administered IV every 21 days; G-CSF administered subcutaneously (SC) starting approximately 24 hours after each prexasertib dose every 21 days. Part A3: Cisplatin administered IV on day one and prexasertib administered IV on day two once every 21 days. Part A Expansion: Part A, A2, and/or A3 may be expanded at the recommended dose. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + Cetuximab (Part B) Prexasertib Part B: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days. Part B2: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days; G-CSF administered SC starting approximately 24 hours after each prexasertib dose every 14 days. Part B3: Cetuximab administered IV with prexasertib administered IV once every 14 days. Part B Expansion: Part B, B2 and/or B3 may be expanded at the recommended dose. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + Pemetrexed (Part C) Prexasertib Part C: Pemetrexed administered IV on day one and prexasertib administered IV on day one and two every 21 days. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + 5-FU (Part D) Prexasertib Part D: Leucovorin administered IV on day one, 5-FU administered IV bolus on day one and by continuous IV on days one to three (46 hours), and prexasertib administered IV on day three every 14 days. Participants may remain on treatment until discontinuation criteria are met. Prexasertib + LY3023414 (Part E) Prexasertib Part E: Prexasertib administered IV on day one and LY3023414 administered orally twice daily every 14 days. Part E will be expanded at the recommended dose in participants with advanced or metastatic cancer, participants with PIK3CA mutations (E2 expansion), or with advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer (E3 expansion). Participants may remain on treatment until discontinuation criteria are met.
- Primary Outcome Measures
Name Time Method Part B: Maximum Tolerated Dose of Prexasertib in Combination with Cetuximab Cycle 1 predose through last dose last cycle (estimated up to 24 weeks) Part D: Maximum Tolerated Dose of Prexasertib in Combination with Fluorouracil (5-FU) Cycle 1 predose through last dose last cycle (estimated up to 24 weeks) Part E: Maximum Tolerated Dose of Prexasertib in Combination with LY3023414 Cycle 1 predose through last dose last cycle (estimated up to 24 weeks) Part C: Maximum Tolerated Dose of Prexasertib in Combination with Pemetrexed Cycle 1 predose through last dose last cycle (estimated up to 24 weeks) Part A: Maximum Tolerated Dose and Schedule of Prexasertib in Combination with Cisplatin Cycle 1 predose through last dose last cycle (estimated up to 24 weeks)
- Secondary Outcome Measures
Name Time Method Pharmacokinetics: Maximum Plasma Concentration of Cetuximab Cycle 1 Predose through Cycle 3, Day 1 Pharmacokinetics: Maximum Plasma Concentration of Prexasertib Cycle 1 Predose through Cycle 2, Day 15 Pharmacokinetics: Maximum Plasma Concentration of Cisplatin (Total Platinum) Cycle 1 Predose through Cycle 2, Day 1 Pharmacokinetics: Area Under the Plasma Concentration Curve of LY3023414 Time Frame: Cycle 1 Predose through Cycle 2, Day 2 B2, E2, E3 Dose Expansion: Overall Response Rate Baseline through disease progression (estimated as up to 24 weeks) or death from any cause B2, E2, E3 Dose Expansion: Disease Control Rate Baseline through disease progression (estimated as up to 24 weeks) or death from any cause B2, E2, E3 Dose Expansion: Progression-Free Survival Baseline through disease progression (estimated as up to 24 weeks) or death from any cause B2, E2, E3 Dose Expansion: Duration of Response Baseline through disease progression (estimated as up to 24 weeks) or death from any cause Pharmacokinetics: Area Under the Plasma Concentration Curve of Prexasertib Cycle 1 Predose through Cycle 2, Day 15 Pharmacokinetics: Maximum Plasma Concentration of Pemetrexed Cycle 1 Predose through Cycle 1, Day 2 Pharmacokinetics: Area Under the Plasma Concentration Curve of Pemetrexed Cycle 1 Predose through Cycle 1, Day 2 Pharmacokinetics: Maximum Plasma Concentration of 5-FU Cycle 1 Predose through Cycle 1, Day 3 Pharmacokinetics: Area Under the Plasma Concentration Curve of Cisplatin (Total Platinum) Cycle 1 Predose through Cycle 2, Day 1 Pharmacokinetics: Maximum Plasma Concentration of LY3023414 Cycle 1 Predose through Cycle 2, Day 2
Trial Locations
- Locations (5)
Sarah Cannon Research Institute SCRI
🇺🇸Nashville, Tennessee, United States
Tennessee Oncology PLLC
🇺🇸Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
University of Oklahoma Health Sciences Center
🇺🇸Oklahoma City, Oklahoma, United States
Florida Cancer Specialists
🇺🇸Sarasota, Florida, United States